Dow Jones

38,686.32

1.51%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

NXTC

NextCure (NXTC)

NextCure Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NXTC

1 2 3 4 5 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
30/05/2024	15:05	GlobeNewswire Inc.	NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024	NASDAQ:NXTC	NextCure Inc
02/05/2024	15:05	GlobeNewswire Inc.	NextCure Provides Business Update and Reports First Quarter 2024 Financial Results	NASDAQ:NXTC	NextCure Inc
24/04/2024	15:05	GlobeNewswire Inc.	NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024	NASDAQ:NXTC	NextCure Inc
08/04/2024	06:00	GlobeNewswire Inc.	NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024	NASDAQ:NXTC	NextCure Inc
04/04/2024	06:05	GlobeNewswire Inc.	NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board	NASDAQ:NXTC	NextCure Inc
02/04/2024	06:00	GlobeNewswire Inc.	NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:NXTC	NextCure Inc
21/03/2024	07:55	GlobeNewswire Inc.	NextCure Provides Business Update and Reports Full Year 2023 Financial Results	NASDAQ:NXTC	NextCure Inc
05/03/2024	07:05	GlobeNewswire Inc.	NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances	NASDAQ:NXTC	NextCure Inc
01/02/2024	15:45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NXTC	NextCure Inc
18/01/2024	15:05	GlobeNewswire Inc.	NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders	NASDAQ:NXTC	NextCure Inc
21/12/2023	06:05	GlobeNewswire Inc.	NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	NASDAQ:NXTC	NextCure Inc
14/12/2023	06:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NXTC	NextCure Inc
14/12/2023	05:45	GlobeNewswire Inc.	NextCure Provides Year-End Clinical Pipeline Updates	NASDAQ:NXTC	NextCure Inc
20/11/2023	06:00	GlobeNewswire Inc.	NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference	NASDAQ:NXTC	NextCure Inc
15/11/2023	15:05	GlobeNewswire Inc.	NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML	NASDAQ:NXTC	NextCure Inc
02/11/2023	15:20	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NXTC	NextCure Inc
02/11/2023	15:05	GlobeNewswire Inc.	NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results	NASDAQ:NXTC	NextCure Inc
17/10/2023	07:05	GlobeNewswire Inc.	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)	NASDAQ:NXTC	NextCure Inc
26/09/2023	15:05	GlobeNewswire Inc.	NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease	NASDAQ:NXTC	NextCure Inc
12/09/2023	07:05	GlobeNewswire Inc.	A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC	NASDAQ:NXTC	NextCure Inc
07/09/2023	15:05	GlobeNewswire Inc.	NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen	NASDAQ:NXTC	NextCure Inc
05/09/2023	15:05	GlobeNewswire Inc.	Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease	NASDAQ:NXTC	NextCure Inc
31/08/2023	06:00	GlobeNewswire Inc.	NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:NXTC	NextCure Inc
04/08/2023	15:58	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:NXTC	NextCure Inc
04/08/2023	15:30	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:NXTC	NextCure Inc
03/08/2023	15:05	GlobeNewswire Inc.	NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results	NASDAQ:NXTC	NextCure Inc
26/06/2023	05:08	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:NXTC	NextCure Inc
23/06/2023	15:32	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:NXTC	NextCure Inc
21/06/2023	15:05	GlobeNewswire Inc.	NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting	NASDAQ:NXTC	NextCure Inc
09/05/2023	06:00	GlobeNewswire Inc.	NextCure to Present at the JMP Securities Life Sciences Conference	NASDAQ:NXTC	NextCure Inc